Promedius, a global medical artificial intelligence startup, announced today that it has signed a memorandum of understanding (MOU) with the Korean Sarcopenia Society for ‘the promotion of musculoskeletal-specialized solution research and development.’

Promedius is a startup that revolutionizes the field of medical AI through solutions that can assist early detection and management of musculoskeletal and metabolic diseases including osteoporosis. The two sides plan to advance their flagship solutions through R&D and commercialization capabilities in their respective fields of expertise, including medical AI and musculoskeletal research; Promedius will further consolidate this partnership as a gold sponsor of the 2024 Korean Congress of Sarcopenia.

Promedius owns a solution that performs automatic segmentation and analysis of muscle and fat areas, providing key metabolic indicators in a report format using abdominal CT images. The company also developed a chest X-ray based screening solution for osteoporosis, which is closely related to sarcopenia, and is currently focusing on commercializing the solution.

"We are pleased that our collaboration with Promedius will open up new possibilities in the field of musculoskeletal disease research and treatment," said Jun-Il Yoo, the Secretary General of the Korean Sarcopenic Society, "through our collaboration, we will be able to reduce the societal cost of musculoskeletal diseases and improve the quality of life of patients."

On March 16, Promedius will also participate in the upcoming Korean Sarcopenia Society's Spring Annual Conference. This event is particularly attention-drawing for Promedius as it will be the company's first Korean conference appearance in 2024, following the completion of the Series A investment from VCs and top-tier investors specializing in biohealthcare.